The Paediatric Protocol Paradox: Does Greater Treatment Intensity Improve Survival in Adolescents and Young Adults with AML?

Background: For adolescents and young adults (AYAs) with acute myeloid leukaemia (AML), more treatment does not necessarily mean more life. Caught between paediatric protocols that often favour greater cytotoxic intensity and adult approaches that more readily incorporate risk-adapted consolidation, young people sit at therapeutic crossroads where the “right” pathway remains contested [1-3]. Paediatric intensity may suppress relapse, but greater disease control may come at the cost of the very survival it is intended to protect [2,3]. This review interrogates that paradox: does treating adolescents with AML similarly to children actually help them live longer - or simply change what puts their survival at risk?

Methods: A structured search of PubMed and Google Scholar identified original comparative studies examining paediatric and adult treatment approaches in adolescents and young adults with AML. The analysis asked not simply which pathway produced better survival, but what was gained - and what was lost - in getting there. Five studies spanning cooperative-group trials, population-based cohorts and contemporary single-centre data were synthesised. Rather than reducing outcomes to survival alone, the evidence was mapped across four domains: treatment intensity, relapse and disease control, treatment-related mortality, and transplantation strategy.

Learning points: The literature revealed a contradiction at the heart of AYA AML treatment: the pathway most successful at preventing leukaemia from returning was not always the one most successful at keeping patients alive. Among 517 AYAs, paediatric COG protocols nearly halved 10-year relapse versus adult CALGB/SWOG protocols (29% vs 57%, p<0.001), yet more than doubled post-remission treatment-related mortality (26% vs 12%, p<0.001) [2]. This resurfaced beyond clinical trials: in 140 AYAs, paediatric-centre care reduced relapse/progression (33.3% vs 56.2%, p=0.002), but increased treatment-related mortality (23.5% vs 10.1%, p=0.046), leaving no overall survival advantage [3].

More recent evidence unsettles the binary further. In 81 AYAs treated between 2010-2025, paediatric and adult approaches achieved near-identical remission (78% vs 79%) and relapse-free survival, despite five-year overall survival numerically favouring adult-service care (56.7% vs 77.9%). Once risk was accounted for, protocol itself lost its prognostic power; molecular risk did not [5]. Across decades of changing treatment, the question therefore shifted: perhaps the problem is not whether AYAs should be treated as children or adults, but why age still decides the doorway through which they enter AML care.

Discussion: Perhaps the paradox was never paediatric versus adult treatment, but the insistence that AYAs must fit neatly into either. Greater control of relapse has repeatedly been tempered by the cost of treatment itself, challenging the assumption that greater intensity means greater survival. AYA AML demands a pathway where molecular risk and treatment response determine intensity, transplantation is individualised, and preventing treatment-related death matters as fiercely as preventing relapse. Success cannot be measured only by whether leukaemia returns, but by whether the young person survives the treatment designed to prevent it. The future may therefore lie beyond the paediatric-adult divide: not in deciding which system these patients belong to, but in building a system that finally belongs to them.